Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the efficacy and safety of DWJ108J (Leuprorelin acetate 11.25 mg) in patients with central precocious puberty.
The drug in this study is called leuprorelin. It is administered as a 3 month subcutaneous depot injection. Leuprorelin is used to treat children who have Central Precocious Puberty. This study will look at whether leuprorelin can stop early Central Precocious Puberty.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental: Leuprorelin | Experimental | Participants with body weight greater than or equal to (≥) 20 kilogram (kg) will receive the recommended dose of leuprorelin 11.25 milligram (mg), injection, subcutaneously, once every 3 months for 6 months. Participants with body weight less than (<) 20 kg will receive leuprorelin 5.625 mg, injection, subcutaneously, once every 3 months for 6 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Leuprolide Acetate 11.25 MG/ML | Drug | Subcutaneous injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. | Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 3 Months. | Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH ≤ 3 IU/L. | 3 months |
| Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Following conditions at Visit 1(Screening) :
Conditions related to pseudo precocious puberty, Incomplete precocious puberty, Dysfunction of pituitary, adrenal, thyroid, or reproductive glands, Growth disorders or bone diseases that could affect bone growth, Brain tumor, Pituitary adenoma
requires treatment within 6 months of receiving a registration number during the trial period that could affect the hypothalamic-pituitary-gonadal axis
Prior treatment with GnRH analogues
Hypersensitive to the investigational drug for this clinical trial or GnRH analogues
Prior or current therapy with growth hormone
has taken the following medications within 8 weeks of Visit 1 (Screening): Sex hormone medications, Sex hormone antagonists, Steroids (local application is allowed; oral formulations are not allowed if taken within 3 days continuously, and use within 2 weeks of screening is prohibited), Herbal medicine
Meets the following criteria based on screening test results:
AST, ALT levels exceed twice the upper limit of normal, Creatinine levels exceed 1.5 times the upper limit of normal, Bone age is above 11.5 years
Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yeonseo Choi, MD. PhD | Contact | 82-2-550-8800 | yeonseo@daewoong.co.kr |
| Name | Affiliation | Role |
|---|---|---|
| Jin Soong Hwang, MD. PhD | Ajou University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ajou University medical center | Recruiting | Gyeonggi-do | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011629 | Puberty, Precocious |
| ID | Term |
|---|---|
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016729 | Leuprolide |
| ID | Term |
|---|---|
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Average LH and FSH concentrations at each time point, and the changes from baseline levels before administration. |
| Baseline, 3 and 6 months |
| Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration | Average LH peak and FSH peak through GnRH stimulation test at 3 and 6 months after administration, and the changes in each time point compared to before administration | 3 and 6 months |
| Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration. | Average concentrations of Estradiol or Testosterone at each time point, and the respective changes compared to before administration. | Baseline, 3 and 6 months |
| Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration. | Average bone age/chronological age ratio at 6 months after administration, and the changes compared to before administration. | 6 months |
| Average Tanner Stage at 6 months after administration, and the changes compared to before administration. | Average Tanner Stage at 6 months after administration, and the changes compared to before administration. | 6 months |
| Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration. | Average growth velocity (cm/year, annualized height velocity) at 6 months after administration, and the changes compared to before administration. | 6 months |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |